These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
389 related articles for article (PubMed ID: 25907003)
1. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P; BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003 [TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P; Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ; Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C BMC Urol; 2015 May; 15():41. PubMed ID: 25956727 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis. Li MC; Wang ZY; Yang J; Guo XL; Wang T; Wang SG; Liu JH; Ye ZQ Asian J Androl; 2015; 17(1):124-34. PubMed ID: 25337836 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687 [TBL] [Abstract][Full Text] [Related]
7. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial. Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853 [TBL] [Abstract][Full Text] [Related]
8. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies. Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P PLoS One; 2017; 12(2):e0170726. PubMed ID: 28166296 [TBL] [Abstract][Full Text] [Related]
9. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms. Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606 [TBL] [Abstract][Full Text] [Related]
10. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe. Rees J; Foley S; Huang M; Rosa Arias J; Skoumal R; Walters C; Yavuz Y; De Wachter S Neurourol Urodyn; 2019 Mar; 38(3):981-989. PubMed ID: 30801782 [TBL] [Abstract][Full Text] [Related]
11. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial. Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559 [TBL] [Abstract][Full Text] [Related]
13. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial. Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246 [TBL] [Abstract][Full Text] [Related]
15. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Hakimi Z; Herdman M; Pavesi M; Devlin N; Nazir J; Hoyle C; Odeyemi IA Qual Life Res; 2017 May; 26(5):1187-1195. PubMed ID: 27896711 [TBL] [Abstract][Full Text] [Related]
16. Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia. Dimitropoulos K; Gravas S Drug Des Devel Ther; 2015; 9():1707-16. PubMed ID: 25834406 [TBL] [Abstract][Full Text] [Related]
17. Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. Mathias SD; Crosby RD; Nazir J; Klaver M; Drogendijk T; Hakimi Z; Odeyemi IA Value Health; 2014 Dec; 17(8):823-9. PubMed ID: 25498777 [TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.]. Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364 [TBL] [Abstract][Full Text] [Related]
20. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]